

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**Form 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) March 21, 2019

---

**AquaBounty Technologies, Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>001-36426</b>	<b>04-3156167</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
<b>2 Mill &amp; Main Place, Suite 395, Maynard, Massachusetts</b>		<b>01754</b>
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code	<b>978-648-6000</b>	

---

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.**

(b) On March 21, 2019, Ronald L. Stotish, Chief Technology Officer of AquaBounty Technologies, Inc. (the "Company"), informed the Company that he would not stand for re-election as a member of the Company's Board of Directors at the

upcoming 2019 Annual Meeting of Stockholders. Following the recent lifting of the FDA's Import Alert that served as the final hurdle to clear before sale of the Company's AquAdvantage Salmon in the United States, Dr. Stotish, 69, who lead the Company's regulatory efforts to obtain approval of AquAdvantage Salmon both in Canada and the United States, has decided that he will retire after thirteen years of service to the Company, effective as of June 30, 2019.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 25, 2019

---

AquaBounty Technologies, Inc.

---

(Registrant)

/s/ David A. Frank

---

David A. Frank

Chief Financial Officer